Moderna, Inc. (NASDAQ:MRNA) is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at ...

Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday and Moderna stock skidded in early action.

The claim that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic is false. His remarks at Davos 2023 ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma, leaving the partners speculating about a possible regulatory ...

Investing.com -- Bank of America lowered its price target on Moderna (NASDAQ:MRNA) to $34 from $41 in a note Tuesday, maintaining an Underperform rating on the stock ahead of the company’s ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ahead of the company reporting Q4 results on Friday ...